{"id":"294359117093-66","name":"UCB","registrationDate":"2015-04-24T10:35:14.049+02:00","category":2,"subCategory":3,"legal":"Public Limited Company","web":"http://www.ucb.com","country":"Belgium","headAddress":"Allée de la Recherche 60","headCity":"Brussels","headPostCode":"1070","headPhone":"(32)25 59 99 99","boss":"Jean-Christophe Tellier","bossTitle":"Mr","bossPosition":"CEO","membersCount":2,"membersFTE":"0.75","membership":"EFPIA = European Federation of Pharmaceutical Industries and Associations&#xd;\n(http://efpia.eu/)&#xd;\n&#xd;\nEBE = European Biopharmaceuticals Entreprises (http://www.ebe-biopharma.eu/)","memberOrga":"","goal":"UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB).","acronym":"","interests":"Competition, Consumers, Digital economy and society, Economy, finance and the euro, Employment and Social Affairs, Public Health, Research and innovation, Single market","euInitiatives":"Engage governments and policymakers worldwide on issues important to UCB to:&#xd;<br />• Ensure patients have access to medicines they need&#xd;<br />• Provide coverage and reimbursement that reward innovation&#xd;<br />• Introduce sound, science-based regulation&#xd;<br />• Enable biotechnology research and development (R&amp;D)","lastUp":"2019-04-10T09:24:29.844+02:00","customers":"","costAbsolu":"","costRange":"200000-299999","turnoverAbsolu":0,"turnoverRange":""}